ClinicalTrials.gg
CompletedNCT00911963Updated Mar 10, 2014

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

A Phase 1/2 interventional study of VCH-222 or matching placebo and VCH-222 or matching placebo in Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 10 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-03-10.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing peginterferon alfa-2a in Hepatitis C — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C.

Enrollment
31st of 49
49 · median 64
Started
2009
with 3 others
Phase 1/2
Only one
of the 49
Registered
24th of 49
by date
Lead sponsor
7 of 49
Vertex Pharmaceuticals Incorporated

Among the 49 studies testing peginterferon alfa-2a in Hepatitis C, this one is the 31st largest by enrollment, is one of 4 that started in 2009, is the only one in phase 1/2, and was the 24th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 49 studies testing peginterferon alfa-2a in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing peginterferon alfa-2a in Hepatitis C as a file.
02

Study summary

The purpose of this study is to assess antiviral activity when administered alone for 3 days or in combination with peginterferon and ribavirin for 12 weeks. This study will also evaluate the safety and tolerability of treatment with VCH-222 when given alone or in combination with peginterferon and ribavirin.

The study will also evaluate the pharmacokinetic profile of VCH-222 in HCV infected subjects.

03

Conditions studied

  • Hepatitis C

Browse trials for

Keywords

  • VX-222
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female subjects, 18-65 years of age (females non-child bearing potential in Part B)
  • Have laboratory evidence of infection for 6 months, defined by (1) presence of anti-HCV antibody (Genotype 1a and 1b infection), or (2)documented HCV RNA presence by a sensitive and specific assay and (3 histologic evidence of CHC (Fibrosis on a standardized histological grading system)
  • Plasma HCV RNA of 100,000 IU/ml
  • 1 and HIV2 ab seronegative
  • (BMI) ≤ 35 kg/m2 BMI
  • Treatment Naive subjects

Exclusion criteria

Exclusion Criteria:

  • to peginterferon or ribavirin therapy
  • Have evidence of liver cirrhosis, decompensated liver disease, and score > 5
  • Have hemoglobinopathies, unstable cardiac disease, history of organ transplant, active malignant disease or uncontrolled Type I or II diabetes
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Part A

    This will be a 4 dose escalation study comparing VCH-222 to placebo treatment.

    Drug: VCH-222 or matching placebo

  • Experimental
    Part B

    VCH-222 + peginterferon alfa-2a + ribavirin (12 weeks) followed by peginterferon alfa-2a + ribavirin for 36 weeks

    Drug: VCH-222 or matching placebo · Biological: peginterferon alfa-2a · Drug: ribavirin

Interventions

  • DrugVCH-222 or matching placebo

    capsule, oral, 4 doses once daily or twice daily, 3 days

    Also known as: VCH-222 is also known as VX-222

  • DrugVCH-222 or matching placebo

    capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks

    Also known as: VCH-222 is also known as VX-222

  • subcutaneous injection, 180 μg, once weekly, 48 weeks

  • tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks

06

What researchers measure

Primary outcomes

  1. To assess the antiviral activity of VCH-222, in subjects with genotype 1 hepatitis C virus (HCV) infection after once (QD) or twice (b.i.d.) daily dosing for 3 days (Part A)

    Time frame: Daily for the first 3 days and at each study visit

  2. To assess the antiviral activity of VCH-222, in subjects with genotype 1 HCV infection after b.i.d. daily dosing for 12 weeks in combination with Peg-interferon-alfa-2a and ribavirin (Part B)

    Time frame: Week 4 and Week 12

  3. Assess the safety and tolerability of VCH-222 when administered in combination with Peg-IFN-alfa-2a/RBV for 12 weeks (Part B)

    Time frame: Study visits throughout part B

Secondary outcomes

  1. To assess the safety and tolerability of VCH-222 when administered for 3 days in monotherapy (Part A)

    Time frame: Study visits throughout Part A

  2. To evaluate the pharmacokinetic (PK) profile of VCH-222 in HCV infected subjects (Part B)

    Time frame: Time points through Part B

07

Study locations

10 sites
  • Gastrointestinal Specialists of Georgia PC
    Marietta, Georgia 30060, United States
  • Henry Ford Health Sytem
    Detroit, Michigan 48202, United States
  • The liver institute at Methodist hospital
    Dallas, Texas 75203, United States
  • Alamo Medical Research
    San Antonio, Texas 78215, United States
  • ACLIRES Argentina SRL
    Buenos Aires, Argentina
  • Hospital Universitario Austral
    Buenos Aires, Argentina
  • Downtown ID Clinic/University of British Columbia
    Vancouver, British Columbia V6Z 2C7, Canada
  • John Buhler Research Centre
    Winnipeg, Manitoba R3E 3P4, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Fundacion de Investigation de Diego
    Santurce, Puerto Rico
08

References and documents

Publications

  • Jiang M, Zhang EZ, Ardzinski A, Tigges A, Davis A, Sullivan JC, Nelson M, Spanks J, Dorrian J, Nicolas O, Bartels DJ, Rao BG, Rijnbrand R, Kieffer TL. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor. Antimicrob Agents Chemother. 2014 Sep;58(9):5456-65. doi: 10.1128/AAC.03052-14. Epub 2014 Jun 30. PubMed 24982088 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2009
First posted
Jun 3, 2009
Start
Apr 2009
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results delay requested
Feb 6, 2014
Last update
Mar 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00911963
Collaborators
ViroChem Pharma
Responsible party
Sponsor
First posted
Jun 3, 2009
Start date
Apr 2009
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Mar 10, 2014

Study contacts

Medical Monitor
study director · Vertex Pharmaceuticals Incorporated

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion